Ipamorelin: Selective, Well-Characterized, and Zero for One in Humans

The short version

Ipamorelin is a synthetic five-amino-acid peptide that activates the ghrelin receptor on the pituitary gland, triggering a pulse of growth hormone release. Its defining feature is selectivity: unlike earlier growth-hormone-releasing peptides, it raises GH without meaningfully elevating cortisol or prolactin, even at doses more than 200 times above its effective threshold ^[6].

Here is the honest accounting. The foundational pharmacology is real and well-characterized — but it is almost entirely animal and early-stage human work. The only controlled human efficacy trial, in 114 patients recovering from bowel surgery, tested ipamorelin against postoperative ileus and did not meet its primary endpoint ^[3]. No Phase 3 trial has ever been conducted. The most common off-label uses circulating in clinics and online — anti-aging, fat loss, muscle gain — rest on receptor mechanism and rodent studies, not human outcome trials. Ipamorelin is not approved anywhere as a drug, and in 2024 the FDA removed it from the 503A compounding category 2 list. This page reports what was studied; it gives no human dose and no medical advice.

What it is

Ipamorelin is a pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 — five amino acids, with an alpha-aminoisobutyric acid at position 1 and D-configured residues at positions 3 and 4 that resist enzymatic breakdown. It was derived from the earlier GHRP-1 by removing a central dipeptide, and it was identified in its founding characterization as a selective agonist of the ghrelin / growth hormone secretagogue receptor (GHS-R1a), which it shares mechanistically with the natural hormone ghrelin ^[6].

Beyond the pituitary, GHS-R1a receptors are present on enteric and vagal neurons, pancreatic islet cells, and hypothalamic appetite circuits — which is why ipamorelin's effects extend beyond a simple GH pulse, and why appetite, insulin, and cardiovascular signals all fall within its plausible range of activity ^[6].

How it works

When ipamorelin binds GHS-R1a on pituitary somatotrophs, it activates a signaling cascade that causes growth hormone to be synthesized and released as a discrete pulse. This mechanism is distinct from and complementary to GHRH, which acts on a different receptor; the two are sometimes combined in research protocols precisely because they operate independently ^[7].

Ipamorelin's published selectivity profile is its most-cited feature. In primary rat pituitary cells, anaesthetized rats, and conscious swine, it released GH potently — with a swine ED50 of 2.3 nmol/kg, comparable to GHRP-6 — while producing no significant elevation in ACTH or cortisol even at doses more than 200-fold above the GH threshold ^[6]. That cortisol sparing distinguishes it from earlier growth-hormone-releasing peptides, which stimulate adrenocortical as well as somatotroph activity.

In healthy male volunteers, intravenous ipamorelin showed dose-proportional pharmacokinetics: terminal half-life approximately 2 hours, clearance 0.078 L/h/kg, steady-state volume of distribution 0.22 L/kg. The GH response peaked at roughly 40 minutes after dosing as a single pulse ^[4]. These are the only published human pharmacokinetic data, and they come from IV infusion in eight subjects per dose level — the subcutaneous route used in off-label research has no published human characterization.

What the research shows

Founding characterization. The 1998 paper established ipamorelin as the first highly GH-selective growth hormone secretagogue, demonstrating potent GH release across rat and swine models without cortisol or ACTH elevation — the finding that defines the compound ^[6].

Bone growth in rats. Subcutaneous ipamorelin at 18, 90, and 450 micrograms per day for 15 days dose-dependently increased the longitudinal bone growth rate of adult female rats from 42 microns per day to up to 52 microns per day, without measurable changes in systemic IGF-1 or bone turnover markers — suggesting partly local or GH-pulse-driven skeletal effects ^[5].

Human pharmacokinetics. Population PK/PD modeling in healthy male volunteers confirmed linear, dose-proportional kinetics and characterized the GH pulse profile ^[4]. This is one of only two controlled human datasets for ipamorelin.

The Phase 2 trial. A prospective, randomized, controlled study (NCT00672074) enrolled 114 adults undergoing bowel resection and gave ipamorelin or placebo IV twice daily for up to 7 days. Median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo — a difference that did not reach statistical significance (p=0.15). The trial did not meet its primary endpoint. Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm versus 94.8% of placebo, with no ipamorelin-specific safety signal identified in this short perioperative window ^[3].

Most recent preclinical study. A 2024 ferret study found that intraperitoneal ipamorelin inhibited cisplatin-induced body-weight loss by approximately 24% on the last day of the delayed phase, but had no anti-emetic effect — unlike the centrally acting anamorelin, which reduced acute emesis by 60%. The result implicates a peripheral mechanism distinct from the central anti-emetic pathway ^[1].

Muscle model, narrative review. A 2026 orthopaedic review reported that combining CJC-1295 with ipamorelin improved maximal muscle tetanic tension in a murine glucocorticoid-induced muscle-loss model, while also concluding that safety and dosing data for ipamorelin remain unknown and significant research is required before any clinical recommendation can be made ^[7].

Reported effects, cautions & safety

Research-use communities report a consistent set of experiences with ipamorelin protocols. These are anecdotal accounts, not clinical findings — uncontrolled, unverified, with unknown dose, source, and confounders. They are recorded here because they are part of the information landscape, not because they constitute evidence.

Reported benefits (anecdotal, not clinical evidence): Deeper, more restorative sleep is the most frequently cited positive report — users describe faster sleep onset, more depth, and better waking recovery, often appearing within one to two weeks of a pre-bed protocol. Vivid or more intense dreams are commonly noted in the first two weeks, typically interpreted as a sign of enhanced REM architecture. Faster physical recovery and reduced post-training soreness are frequently described, along with a gradual shift toward leaner body composition over weeks to months.

Reported adverse effects (anecdotal, not clinical evidence): Facial flushing and a warm head-rush roughly 5–15 minutes post-injection are widely noted — often compared to a niacin flush, typically lasting under an hour. Tingling or numbness in the hands and feet, mild water retention or puffiness, increased hunger, early fatigue or lightheadedness after injection, injection-site redness or itching, and a perceived diminishing response after several months of uninterrupted use are all occasionally reported.

Safety cautions from the literature:

• Unknown long-term human safety. The only controlled human datasets are a PK/PD study in eight volunteers (single acute IV doses) and a 7-day perioperative trial in 114 patients. No long-term human safety data exist. Subcutaneous self-administration — the dominant community practice — has no published human pharmacokinetic characterization ^[3][4].
• Class-level cardiovascular signal. A 28-day study of GSK894281, a structurally distinct GHS-R1a agonist in the same receptor class, found dose-dependent myocardial degeneration and necrosis in rats, detectable by elevated FABP3 and histopathology — a class-level warning about chronic GHS dosing in subjects with cardiac vulnerability. Ipamorelin itself was not the compound tested ^[2].
• Diabetes and insulin dysregulation. GH is a counter-regulatory hormone that reduces insulin sensitivity; ipamorelin also has GH-independent insulinotropic effects on pancreatic islet cells in animal tissue. The combined metabolic impact in subjects with pre-existing insulin resistance is unpredictable ^[6].
• GH/IGF-1 and proliferative conditions. Chronic GH-axis stimulation carries a theoretical concern about IGF-1-driven cell proliferation in subjects with pre-existing or occult tumors — a class-level mechanism, not an observed oncologic event in ipamorelin studies.
• Regulatory and anti-doping. In 2024, the FDA removed ipamorelin acetate from the 503A compounding Category 2 list. Ipamorelin is prohibited in sport at all times under WADA category S2.

Where it fits in GH-axis research

Among the three compounds on this desk, ipamorelin has the most direct human data — a pharmacokinetics study and a Phase 2 efficacy trial — and the clearest mechanistic characterization. The pharmacology is coherent and its selectivity is genuine. What it lacks is a positive human efficacy result for any indication, approved regulatory standing anywhere, and long-term safety data. It represents the GHS-R1a (GHRP) route to GH release, in contrast to CJC-1295 and sermorelin, which act on the GHRH receptor. The comparison page places all three in context.